NRx Pharmaceuticals has a twelve month low of $1.10 and a twelve month high of $6.01. The stock has a market capitalization of $34.68 million, a PE ratio of -0.96 and a beta of 1.22.

BTIG Research assumed coverage on shares of NRx Pharmaceuticals (NASDAQ:NRXP – Free Report) in a research report released on Wednesday morning, MarketBeat reports. The brokerage issued a buy rating ...

Fintel reports that on April 2, 2025, BTIG initiated coverage of NRx Pharmaceuticals (NasdaqCM:NRXP) with a Buy recommendation. Analyst Price Forecast Suggests 1,491.13% Upside As of April 2 ...

Hope Therapeutics, an interventional psychiatry network wholly owned by NRx Pharmaceuticals (NRXP), announced signing of a definitive agreement ...

Shares of NRx Pharmaceuticals, Inc. (NRXP) have been struggling lately and have lost 5.1% over the past week. However, a hammer chart pattern was formed in its last trading session, which could ...

Investing.com – U.S. stocks were mixed after the close on Tuesday, as gains in the Utilities, Telecoms and Consumer Services ...

As of April 2, 2025, the average one-year price target for NRx Pharmaceuticals is $32.30/share. The forecasts range from a low of $19.19 to a high of $47.25. The average price target represents an ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...